18th May 2015 08:22
LONDON (Alliance News) - Futura Medical PLC said Monday it now expects headline results from its clinical study of three topical pain relief products in mid-July, ahead of its original expectation of the end of July.
Two out of three cohorts of the study have been completed, Futura said, and dosing of the final cohort of its methyl salicylate product SPR300 is expected to begin shortly.
"We are delighted by the progress being made in this clinical study of the three products in our topical pain relief portfolio," said Chief Executive James Barder in a statement. " Our earlier work suggests that our pain relief portfolio is highly competitive, for example, in speed of onset of action of pain relief. We now look forward to receiving the headline data from the study in mid-July this year."
Shares in Futura are trading up 1.9% at 40.00 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Futura Medical